Zacks Investment Research Downgrades Adial Pharmaceuticals (NASDAQ:ADIL) to Hold

Adial Pharmaceuticals (NASDAQ:ADIL – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday, Zacks.com reports. According to Zacks, “Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. […]

Related Keywords

,Adial Pharmaceuticals Inc ,Geode Capital Management ,Goldman Sachs Group Inc ,Zacks Investment Research ,Renaissance Technologies ,Blackrock Inc ,Empirical Financial Services ,Adial Pharmaceuticals ,Adial Pharmaceuticals Get Rating ,Get Rating ,Financial Services ,Empirical Wealth Management ,Sachs Group ,Capital Management ,Nasdaq Adil ,Cadil ,Medical ,Downgrade ,